The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Extraordinary General Meeting (“EGM”), on Thursday January 8, 2026, at 10.00 a.m. (CET), at Cirio Advokatbyrå, Biblioteksgatan 9, in Stockholm. The Board of Directors has resolved that shareholders shall have the right to exercise their voting rights through postal voting pursuant to item 13 in the Articles of Association. Therefore, shareholders may choose to exercise t ...

Core Viewpoint - Karolinska Development AB plans to conduct a rights issue of class B shares to raise approximately SEK 202.6 million for the continued development of existing investments, new investments, and general corporate purposes [2][4]. Rights Issue Details - The rights issue will consist of up to 675,193,985 new class B shares at a subscription price of SEK 0.30 per share, with an estimated transaction cost of SEK 16.8 million [4][9]. - Shareholders will have preferential rights, where one existing share grants five subscription rights, and two subscription rights allow for the purchase of one new class B share [4][9]. - The subscription period is from January 13, 2026, to January 27, 2026, with trading in subscription rights occurring from January 13 to January 22, 2026 [10][11]. Financial Commitments - Existing shareholders and members of the Board have committed approximately SEK 5.2 million, representing about 2.6% of the rights issue, while guarantee commitments total approximately SEK 95.2 million, or about 47% of the rights issue [3][12][13]. - The net proceeds will primarily be allocated to existing portfolio companies (approximately 75%) and general corporate purposes (approximately 25%) [10][8]. Company Background - Karolinska Development is an investment company focused on medical innovations with significant commercial potential, managing a portfolio of eleven companies, nine of which have drug candidates in clinical trials [6][7]. - The company aims to leverage its management expertise and co-investments with other investors to enhance the development and commercialization of its portfolio [7][23]. Extraordinary General Meeting - The rights issue is subject to approval by an Extraordinary General Meeting scheduled for January 8, 2026, which will also consider amendments to the company's articles of association and a proposed name change to KDventures AB [19][20].

Core Viewpoint - Ørsted, the world's largest offshore wind developer, will reduce its workforce by 2,000 positions by 2027, representing a quarter of its current roles, in response to various challenges and to enhance competitiveness in Europe [1][2]. Group 1: Workforce Reduction - Ørsted plans to cut approximately 2,000 jobs by the end of 2027 as part of its strategic focus on Europe and to improve competitiveness [1]. - The decision to reduce the workforce is linked to the completion of its large construction portfolio in the coming years, necessitating fewer employees [2]. Group 2: Financial Measures - Ørsted recently completed a rights issue, raising $9.35 billion (59.56 billion Danish crowns) from existing shareholders to address immediate financing needs and strengthen its capital structure [4][5]. - The rights issue was heavily discounted, priced at 66.60 crowns ($1.04) per share, compared to a closing price of 122.35 crowns ($19.18) [5]. Group 3: Industry Challenges - The offshore wind industry has faced significant challenges, including regulatory changes, cost inflation, and high interest rates, which have negatively impacted project economics [4]. - Ørsted has encountered difficulties in the U.S. market, particularly due to regulatory obstacles under the Trump Administration affecting offshore wind projects [3].

The third-largest shareholder in Orsted plans to participate in the wind developer’s rights issue https://t.co/R8jGZXlCjD ...

Financial Strategy - Orsted 计划发行 94 亿美元（$9.4 billion）的股票[1] Project Funding - 该融资用于海上风电项目[1]

Core Viewpoint - Modus Therapeutics is conducting a fully secured rights issue to raise SEK 28.3 million for the continued development of its drug candidate sevuparin, aimed at treating chronic kidney disease with anemia [1][2][3]. Group 1: Rights Issue Details - The rights issue will provide SEK 28.3 million before issue costs, subject to approval at an extraordinary general meeting on July 29, 2025 [2][3]. - Major shareholders, including Karolinska Development, have committed SEK 17.7 million, covering 62.7% of the rights issue, with the remaining 37.3% underwritten by external parties [4]. Group 2: Purpose and Impact - The funds from the rights issue will be used to complete the ongoing clinical phase II study of sevuparin and to finance operations through the end of 2026 [3]. - The successful securing of the rights issue is viewed as a strong indicator of Modus Therapeutics' clinical strategy and financial health [5]. Group 3: Company Background - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations [6][7]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by experienced management teams and a strong global network [8].